Literature DB >> 22498085

Optimization of mediastinal staging in potential candidates for stereotactic radiosurgery of the chest.

Devadatta Sarwate1, Saiyad Sarkar, William S Krimsky, Constantine M Burgan, Kalpesh Patel, Ruth Evans, Daniel P Harley.   

Abstract

OBJECTIVE: Patients with medically inoperable nonsmall-cell lung cancer generally have limited staging of the mediastinum using computed tomography and combined positron emission tomography and computed tomography, before stereotactic radiosurgery. Historical data have demonstrated the superiority of tissue sampling techniques such as endobronchial ultrasonography and mediastinoscopy compared with imaging studies in accurately determining the nodal stage. We believe, that at a minimum, mediastinal interrogation with endobronchial ultrasonography should be performed before patients undergo stereotactic radiosurgery.
METHODS: A retrospective review of 59 consecutive patients undergoing bronchoscopic fiducial marker placement as potential candidates for stereotactic radiosurgery was done. All these patients had undergone endobronchial ultrasonography to assess the mediastinum. Transbronchial needle aspirates were taken using standard criteria defined by a lymph node size greater than 5 mm in diameter and/or in the appropriate lymph node drainage pathway. The biopsies were reviewed by the institution's pathologists.
RESULTS: Mediastinal lymph node specimens were not taken in 9 patients because they did not meet our criteria. Of the 50 patients who underwent mediastinal lymph node sampling, 10 had evidence of nodal involvement. On review, 2 of these 10 patients had evidence of mediastinal adenopathy on computed tomography. After excluding those 2 patients, the mediastinal lymph nodes were positive for metastatic disease in 8 (16%) of 50 patients without previous radiographic evidence of disease. These patients were previously thought to be suitable candidates for stereotactic radiosurgery. Also 5 of 10 patients with endobronchial ultrasound-positive lymph nodes had had positron emission tomography-negative findings in the mediastinum. Finally, 10% of the patients suspected to have stage II or III were downstaged with endobronchial ultrasonography and considered for stereotactic radiosurgery.
CONCLUSIONS: Endobronchial ultrasonography-transbronchial needle aspirates is more accurate than computed tomography and positron emission tomography in staging the mediastinum, can be performed with minimal morbidity, and should be considered for all patients considered candidates for stereotactic radiosurgery.
Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22498085     DOI: 10.1016/j.jtcvs.2012.03.004

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data.

Authors:  Chad G Rusthoven; Brian D Kavanagh; Sana D Karam
Journal:  Ann Transl Med       Date:  2015-07

2.  Is staging mediastinoscopy necessary before stereotactic body radiotherapy for inoperable early stage lung cancer?

Authors:  Jean-Claude M Rwigema; Percy Lee
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

3.  Impact of invasive nodal staging on regional and distant recurrence rates after SBRT for inoperable stage I NSCLC.

Authors:  William R Kennedy; Pamela P Samson; Prashant Gabani; John Nikitas; Jeffrey D Bradley; Michael C Roach; Clifford G Robinson
Journal:  Radiother Oncol       Date:  2020-07-03       Impact factor: 6.280

4.  Systematic Endobronchial Ultrasound-guided Mediastinal Staging Versus Positron Emission Tomography for Comprehensive Mediastinal Staging in NSCLC Before Radical Radiotherapy of Non-small Cell Lung Cancer: A Pilot Study.

Authors:  Daniel P Steinfort; Shankar Siva; Tracy L Leong; Morgan Rose; Dishan Herath; Phillip Antippa; David L Ball; Louis B Irving
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

5.  Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy.

Authors:  Adil S Akthar; Mark K Ferguson; Matthew Koshy; Wickii T Vigneswaran; Renuka Malik
Journal:  Technol Cancer Res Treat       Date:  2016-06-23

6.  Safety and feasibility of prolonged bronchoscopy involving diagnosis of lung cancer, systematic nodal staging, and fiducial marker placement in a high-risk population.

Authors:  Harman Kular; Lakshmi Mudambi; Donald R Lazarus; Lorraine Cornwell; Angela Zhu; Roberto F Casal
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

7.  MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma.

Authors:  Wei Meng; Zhenqing Ye; Ri Cui; James Perry; Vaia Dedousi-Huebner; Alexander Huebner; Yao Wang; Bin Li; Stefano Volinia; Hiroshi Nakanishi; Taewan Kim; Sung-Suk Suh; Leona W Ayers; Patrick Ross; Carlo M Croce; Arnab Chakravarti; Victor X Jin; Tim Lautenschlaeger
Journal:  Clin Cancer Res       Date:  2013-08-14       Impact factor: 12.531

8.  Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic Experience.

Authors:  Corey J Hobbs; Stephen J Ko; Nitesh N Paryani; Joseph M Accurso; Kenneth R Olivier; Yolanda I Garces; Sean S Park; Christopher L Hallemeier; Steven E Schild; Sujay A Vora; Jonathan B Ashman; William G Rule; Johnny R Bowers; Michael G Heckman; Nancy N Diehl; Robert C Miller
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2017-12-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.